Clinical trial
Risk Factors for Severe Disease in Hospitalized Patients With COVID-19 and the Effect
Name
ZDWY.BAS.001
Description
The purpose of this study is to explore the factors that can affect the development of severe cases in hospitalized patients with COVID-19, including basic diseases, laboratory parameters, and clinical manifestations; In addition,to explore whether Azvudine can reduce the mortality of hospitalized patients with COVID-19.
Trial arms
Trial start
2023-08-05
Estimated PCD
2023-10-25
Trial end
2023-10-30
Status
Active (not recruiting)
Treatment
Azvudine
Received antiviral treatment with azvudine
Arms:
Azvudine group
Size
4201
Primary endpoint
All-cause mortality of COVID-19 patients
Time from onset to death
Eligibility criteria
Inclusion Criteria:
The COVID-19 positive patients
Exclusion Criteria:
1. patients treated with both azvudine and monotamivir;
2. patients receiving other antiviral drugs such as nematavir/ritonavir;
3. age \< 18 years old
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 4201, 'type': 'ESTIMATED'}}
Updated at
2023-09-21
1 organization
1 product
1 indication
Product
AzvudineIndication
COVID-19